Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma

Cremerius, U.; Fabry, U.; Neuerburg, J; Zimny, M.; Osieka, R.; Buell, Udalrich

doi:10.1097/00006231-199811000-00005

Cited by 133 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although 67-Gallium scintigraphy is a metabolic imaging technique to detect active tumour tissue, it has drawbacks such as a low spatial resolution and difficulty in identifying residual abdominal masses (Kostakoglu et al, 1992;Setoain et al, 1997;Zinzani et al, 1999a, b). In recent years, a series of reports have shown that PET is the most helpful noninvasive metabolic imaging technique for patients with either HD or aggressive NHL: it can distinguish between active lymphoma and fibrosis, and it has important prognostic value after completion of front-line therapy (Cremerius et al, 1998(Cremerius et al, , 2001De Wit et al, 2001;Naumann et al, 2001;Spaepen et al, 2001a, b;Weihrauch et al, 2001Weihrauch et al, , 2003Zinzani et al, 2002;Fihnont et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…For these purposes, functional imaging with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can reveal decisive metabolic or functional tissue parameters and is more accurate than conventional radiological imaging techniques for restaging after chemotherapy (Jerusalem et al, 1999(Jerusalem et al, , 2001Zinzani et al, 1999a, b;Kostakoglu and Goldsmith, 2000;Dittmann et al, 2001). Several groups, including our own, have evaluated the efficiency of PET for restaging patients after completed therapy (Cremerius et al, 1998(Cremerius et al, , 2001De Wit et al, 2001;Naumann et al, 2001;Spaepen et al, 2001a, b;Weihrauch et al, 2001Weihrauch et al, , 2003Zinzani et al, 2002;Fihnont et al, 2003).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

et al. 2004

View full text Add to dashboard Cite

An extensive analysis of the reliability of positron emission tomography (PET) after induction treatment in patients with Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL). In all, 75 untreated patients with HD (n ¼ 41) or aggressive NHL (n ¼ 34) were studied with both PET and CT scans following standard chemotherapy induction therapy (ABVD or MACOP-B) with/ without radiotherapy. Histopathological analysis was performed when considered necessary. After treatment, four out of five (80%) patients who were PET þ /CT À relapsed, as compared with zero out of 29 patients in the PET À /CT À subset. Among the 41 CT þ patients, 10 out of 11 (91%) who were PET þ relapsed, as compared with 0 out of 30 who were PET À . The actuarial relapse-free survival (RFS) rates were 9 and 100% in the PET þ and PET À subsets, respectively (P ¼ 0.00001). All five patients who were PET þ / CT À underwent a lymph node biopsy: in four (80%) cases, persistent lymphoma and was confirmed at histopathological examination. Two HD patients who were PET À /CT þ (with large residual masses in the mediastinum or lung) were submitted to biopsy, which in both cases revealed only fibrosis. In HD and aggressive NHL patients, PET positivity after induction treatment is highly predictive for the presence of residual disease, with significant differences being observable in terms of RFS. PET negativity at restaging strongly suggests the absence of active disease; histopathological verification is important in patients who show PET positivity.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, it is cumbersome to perform and insensitive for detecting residual disease. Recently, several studies showed that FDG PET can be an alternative tool to overcome these limitations of anatomic imaging and Ga-67 scans in malignant lymphomas (22)(23)(24)(25)(26)(27)(28)(29)(30). These data, however, have been obtained with dedicated PET cameras.…”

Section: Discussionmentioning

confidence: 99%

“…Paul (17) first described imaging lymphomas with FDG in 1987. Published results indicate that FDG PET may be superior to planar Ga-67 scanning (18 -21) and equal or superior to CT for the detection of nodal and extranodal involvement in lymphomas (22)(23)(24)(25)(26)(27)(28)(29)(30)(31). Dedicated PET, however, has not been used widely in lymphomas because of the high cost of its operation.…”

mentioning

confidence: 99%

Imaging of Malignant Lymphomas with F-18 FDG Coincidence Detection Positron Emission Tomography

Hwang¹,

Park²,

Kim³

et al. 2000

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…Preliminary data suggest that FDG-PET is a useful tool to stage and monitor lymphoma. [13][14][15][16][17][18][19][20][21][22][23] However, there has been scarce data comparing FDG-PET and Ga-67 scintigraphy; thus, their comparative value is still conjectural. 13,24,25 Accordingly, we prospectively compared the accuracy of whole-body FDG-PET and Ga-67 scintigraphy to identify disease sites in HD and non-Hodgkin lymphoma (NHL; intermediate grade and high grade) at initial staging or recurrence before chemotherapy.…”

mentioning

confidence: 99%

Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

Kostakoğlu

Leonard

Kuji

et al. 2002

Cancer

179

View full text Add to dashboard Cite

Ga-67 SPECT failed to demonstrate disease at 45 sites (35.7%). In 10 of 44 patients, Ga-67 SPECT completely failed to detect any disease at 22 of 45 sites (17.5%) and partially identified disease sites at 23 of 45 sites (18.2%) in 11 patients regardless of the tumor site and histology. In these patients, the lesions measured between 0.6 and 14.0 cm by CT. Fluorodeoxyglucose positron emission tomography revealed higher stage disease in 13 patients compared with Ga-67 imaging. Tumor-tobackground ratios were statistically different between the two techniques with

show abstract

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma

Cited by 133 publications

References 0 publications

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

Imaging of Malignant Lymphomas with F-18 FDG Coincidence Detection Positron Emission Tomography

Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

Contact Info

Product

Resources

About